Ascendis Pharma A (ASND) EBT Margin (2014 - 2026)
Ascendis Pharma A (ASND) posted EBT Margin of 19.54% for Q1 2026, down 204.66% sequentially from 6.41% in Q4 2025, and up 7314.0% YoY from 0.26% in Q1 2025.
Ascendis Pharma A (ASND) EBT Margin (2014 - 2026) Analysis & Trends
Ascendis Pharma A has reported EBT Margin for 13 years, with the latest figure at 19.54% in Q1 2026.
- Quarterly EBT Margin rose 7314.0% year-over-year to 19.54% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 16.15% (up 5124.0% YoY) and the FY2025 annual result came in at 29.53%, up 6245.0% from the prior year.
- EBT Margin fell to 19.54% in Q1 2026 per ASND's latest filing, from 6.41% in the prior quarter.
- Over five years, EBT Margin peaked at 6.41% in Q4 2025 and troughed at 1834.46% in Q1 2022.
- A 5-year average of 405.34% and a median of 169.76% in 2024 frame the typical range for EBT Margin.
- The widest YoY moves for EBT Margin: up 1183392 bps in 2022, down 75932 bps in 2022.
- Over 5 years, EBT Margin stood at 882.6% in 2022, then soared by 97 bps to 26.79% in 2023, then soared by 55 bps to 12.06% in 2024, then jumped by 47 bps to 6.41% in 2025, then sank by 205 bps to 19.54% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 19.54%, 6.41%, and 26.86% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Ascendis Pharma A | 15.40 Bn | 14.73 Bn | 268.20 Mn | -19.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.54% |
| Dec 31, 2025 | -6.41% |
| Sep 30, 2025 | -26.86% |
| Jun 30, 2025 | -22.15% |
| Mar 31, 2025 | -92.68% |
| Dec 31, 2024 | -12.06% |
| Sep 30, 2024 | -169.76% |
| Jun 30, 2024 | -303.21% |
| Mar 31, 2024 | -134.03% |
| Dec 31, 2023 | -26.79% |
| Sep 30, 2023 | -336.38% |
| Jun 30, 2023 | -257.13% |
| Mar 31, 2023 | -326.35% |
| Dec 31, 2022 | -882.60% |
| Sep 30, 2022 | -1,119.44% |
| Jun 30, 2022 | -1,320.88% |
| Mar 31, 2022 | -1,834.46% |
| Dec 31, 2021 | -123.27% |
| Sep 30, 2021 | -7,218.60% |
| Jun 30, 2021 | -13,154.79% |